TheodoreBruceMooreMD

Pediatric Hematology & Oncology • Los Angeles, CA

UCLA

Join to view full profile

Dr. Moore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moore's full profile

Already have an account?

Office
10833 Le Conte Ave
# 12-441
Los Angeles, CA 90095
Phone+1 310-825-6708

Fax+1 310-206-8089

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 1992 - 1995
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1989 - 1992
Oregon Health and Science University School of MedicineClass of 1989

Certifications & Licensure

OR State Medical License 1997 - Present
CA State Medical License 1990 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Start of enrollment: 2006 Dec 01
Completed
Phase 3
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) Start of enrollment: 2008 Aug 01
Completed
Phase 2
Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
Enrolling by invitation
Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
Enrolling by invitation
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease Start of enrollment: 2012 Jan 01
Active, not recruiting
Phase 2
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Start of enrollment: 2013 Jun 24
Completed
Phase 2
Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene Start of enrollment: 2013 Aug 02
Completed
Phase 1, Phase 2
Stem Cell Gene Therapy for Sickle Cell Disease Start of enrollment: 2014 Dec 01
Active, not recruiting
Phase 1, Phase 2
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID Start of enrollment: 2016 Dec 16
Completed
Phase 1, Phase 2
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease Start of enrollment: 2017 Jul 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant Start of enrollment: 2020 Jul 01
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Start of enrollment: 2023 Jan 25
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.
Jack Pengfei Tang, Penelope Lafeuille, Alexandru Socolov, Sheila S Diamond, Jacob Aptekar
Cancer Research Communications. 2024-10-01
1 citations
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
Matt S Zinter, Christopher C Dvorak, Madeline Y Mayday, Gustavo Reyes, Miriam R Simon
Nature Medicine. 2024-07-01
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia.
Roshini S Abraham, Amrita Basu, Jennifer R Heimall, Elizabeth Dunn, Alison Yip
Clinical Immunology. 2024-04-01

Journal Articles

The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...
Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature

Abstracts/Posters

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Pa...
Theodore B. Moore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Precision Medicine in Pediatric Neurooncology: A ReviewDecember 2017

Press Mentions

10 Ways an FIU Online Degree Enhances CareersJuly 7th, 2021
Pediatric Cancer Researchers Receive Grants from St. Baldrick’s FoundationApril 17th, 2018

Grant Support

Phase I Dose Escalation Study Of Autologous Tumor Lysate-Pulsed Dendritic CELNational Center For Research Resources2006
OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe Idiopathic ThroNational Center For Research Resources2005
Impact Of Body Composition On Pharmacokinetics Of Doxorubicin In Pediatric PANational Center For Research Resources2005
OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe Idiopathic Thro...National Center For Research Resources2004
Impact Of Body Composition On Pharmacokinetics Of Doxorubicin In Pediatric Pa...National Center For Research Resources2004
Mechanism N-MYC Oncogene DOWN Regulation By Vitamin DNational Cancer Institute1995